

2023-2024

American Heart Association

Funding from Pharmaceutical and Biotech Companies and Device Manufacturers

We value the trust placed in us by our donors, supporters, and the general public, and we feel the best way to continue to earn that trust is to make the association’s finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau’s Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations, and estates as well as revenue from the sale of mission-aligned products and services, such as CPR training, and investment earnings.

Financial support from corporations helps the association’s programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association’s corporate relations policies and are approved by a committee of national volunteers and executive staff.

Total corporate funding is comprised of unrestricted gifts, special event and program sponsorships and fees from program-related services. Corporate funding represents approximately 15 percent of the AHA’s \$1.3 billion total revenue.

Funding that the American Heart Association receives from pharmaceutical and biotech companies and device manufacturers is included within total corporate funding and represents approximately 3 percent of the association’s total revenue.

The revenue figures below include the total amount of funds earned or committed to the American Heart Association during fiscal year 2023-2024, noting that, in some cases, the funds will be received in future years. The chart provides funds from pharmaceutical and biotech companies and device manufacturers in proportion to all sources of revenue.



Following is a schedule of corporate funding provided to the American Heart Association from pharmaceutical and biotech companies and medical device manufacturers during fiscal year 2023-2024. The schedule reflects cash received during fiscal year 2023-2024 and revenue committed to the American Heart Association that will be received in future years.

2023-2024 Corporate Funding Received from Pharmaceutical and Biotech Companies and Device Manufacturers		
Corporation	Total Cash Received During 2023-2024 on Prior and Current Year Commitments (1)	2023-2024 Commitments Receivable in the Future
Abbott	710,500	165,000
Alexion Pharmaceuticals Inc.	-	675,000
Alnylam Pharmaceuticals	150,000	150,000
Amgen, Inc.	3,100,000	812,500
Astellas Pharma Inc.	125,000	-
AstraZeneca	2,077,757	50,000
AtriCure, Inc.	160,000	250,000
Bayer Healthcare Pharmaceuticals, Inc.	142,500	300,000
Boehringer Ingelheim	3,100,000	3,000,000
Boston Scientific	131,500	25,000
BridgeBio	75,000	-
Bristol Myers Squibb	1,302,155	3,786,497
Cerenovus	55,000	-
Chiesi USA, Inc.	40,000	15,000
CSL Behring	429,500	20,000
Cytokinetics, Incorporated	355,500	450,000
Edwards Lifesciences	3,295,500	673,000
Eli Lilly	370,000	-
Genentech	165,000	-
Ipsen Biopharmaceuticals, Inc.	155,000	144,000
Janssen Pharmaceuticals	105,000	-
Johnson & Johnson	375,580	265,000
Kaneka LLC	264,000	-
Kiniksa Pharmaceuticals	1,679,000	3,031,000
Laerdal	596,666	-
Lantheus	-	60,000
Lexicon Pharmaceuticals, Inc.	150,000	75,000
Medtronic	1,022,000	115,000
Merck Sharp & Dohme LLC	1,327,594	1,250,000
Milestone Pharmaceuticals	265,000	315,000
Novartis	12,206,825	2,468,840
Novo Nordisk, Inc.	7,090,500	7,500
Pfizer	1,313,550	105,000
Phlow	50,000	-
Regeneron Pharmaceuticals, Inc.	220,000	-
Roche Diagnostics	102,019	-
Sanofi	400,000	-
Schiller Americas, Inc.	150,227	50,000
Siemens Industry, Inc.	20,000	37,500
Stryker Instruments	45,000	20,000
Zoll Medical Corporation	107,500	400,000
	<u>43,430,373</u>	<u>18,715,837</u>

NOTE: (1) Includes all cash received from corporate contributions greater than \$50,000. Revenue related to the cash receipts was recorded within AHA's financial statements over the periods from fiscal year 2020-2021 through fiscal year 2023-2024.